BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34102787)

  • 1. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene.
    Tamer F; Gulekon A
    J Coll Physicians Surg Pak; 2021 Jun; 31(6):716-718. PubMed ID: 34102787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas.
    Gregoriou S; Rigopoulos D; Stamou C; Nikolaou V; Kontochristopoulos G
    J Cutan Med Surg; 2013; 17(1):52-4. PubMed ID: 23364151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M; García-Arpa M; González-García J
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA].
    Wirtz M; Helbig D
    Hautarzt; 2014 Apr; 65(4):274-6. PubMed ID: 24671704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK; Lebwohl M
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term control of mycosis fungoides of the hands with topical bexarotene.
    Lain T; Talpur R; Duvic M
    Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
    Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
    Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
    Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
    Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular mycosis fungoides: variability of a rare entity.
    Roeschm A; Schleyer V; Landthaler M; Vogt T
    Skinmed; 2005; 4(1):12-7. PubMed ID: 15654159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular mycosis fungoides: successful treatment with oral bexarotene.
    Shistik G; Scalf LA; Fenske N; Glass LF
    J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
    D'Acunto C; Gurioli C; Neri I
    J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab.
    Hisamoto T; Suga H; Kawana Y; Oka T; Miyagaki T; Sugaya M; Sato S
    Dermatol Ther; 2021 Mar; 34(2):e14805. PubMed ID: 33486865
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Lewis DJ; Huang S; Duvic M
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
    Coors EA; Von den Driesch P
    Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA.
    Krönke A; Schlaak M; Arin M; Mauch C; Kurschat P
    Eur J Dermatol; 2012; 22(2):259-60. PubMed ID: 22240623
    [No Abstract]   [Full Text] [Related]  

  • 19. Interventions for mycosis fungoides.
    Valipour A; Jäger M; Wu P; Schmitt J; Bunch C; Weberschock T
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008946. PubMed ID: 32632956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folliculotropic mycosis fungoides responding to bexarotene gel.
    Walling HW; Swick BL; Gerami P; Scupham RK
    J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.